Overview

Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination

Status:
Completed

Trial end date:
2015-01-13

Target enrollment:

Participant gender:

Summary

The objective of the study is to determine the efficacy and toxicity of sorafenib in metastatic uveal melanoma. The main objective is to determine the non-tumor progression rate 24 weeks after initiation of treatment with sorafenib at a dose of 800 mg / day

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Caen

Treatments:

Sorafenib